These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
373 related articles for article (PubMed ID: 23832066)
1. Companion-diagnostic testing limited to KRAS codons 12 and 13 misses 17% of potentially relevant RAS mutations in colorectal cancer. Netzel BC; Grebe SK Clin Chim Acta; 2013 Oct; 425():1-2. PubMed ID: 23832066 [TBL] [Abstract][Full Text] [Related]
2. KRAS gene mutation in a series of unselected colorectal carcinoma patients with prognostic morphological correlations: a pyrosequencing method improved by nested PCR. de Macêdo MP; de Melo FM; Lisboa BC; Andrade LD; de Souza Begnami MD; Junior SA; Ribeiro HS; Soares FA; Carraro DM; da Cunha IW Exp Mol Pathol; 2015 Jun; 98(3):563-7. PubMed ID: 25835782 [TBL] [Abstract][Full Text] [Related]
3. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Neumann J; Zeindl-Eberhart E; Kirchner T; Jung A Pathol Res Pract; 2009; 205(12):858-62. PubMed ID: 19679400 [TBL] [Abstract][Full Text] [Related]
7. KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies. Maus MK; Grimminger PP; Mack PC; Astrow SH; Stephens C; Zeger G; Hsiang J; Brabender J; Friedrich M; Alakus H; Hölscher AH; Lara P; Danenberg KD; Lenz HJ; Gandara DR Lung Cancer; 2014 Feb; 83(2):163-7. PubMed ID: 24331409 [TBL] [Abstract][Full Text] [Related]
8. [Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma]. Ling Y; Ying JM; Qiu T; Shan L; Guo L; Lü N Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):590-4. PubMed ID: 23157825 [TBL] [Abstract][Full Text] [Related]
9. Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Vaughn CP; Zobell SD; Furtado LV; Baker CL; Samowitz WS Genes Chromosomes Cancer; 2011 May; 50(5):307-12. PubMed ID: 21305640 [TBL] [Abstract][Full Text] [Related]
10. Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients. Taniguchi H; Yamazaki K; Yoshino T; Muro K; Yatabe Y; Watanabe T; Ebi H; Ochiai A; Baba E; Tsuchihara K; Cancer Sci; 2015 Mar; 106(3):324-7. PubMed ID: 25800101 [TBL] [Abstract][Full Text] [Related]
11. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Molinari F; Felicioni L; Buscarino M; De Dosso S; Buttitta F; Malatesta S; Movilia A; Luoni M; Boldorini R; Alabiso O; Girlando S; Soini B; Spitale A; Di Nicolantonio F; Saletti P; Crippa S; Mazzucchelli L; Marchetti A; Bardelli A; Frattini M Clin Cancer Res; 2011 Jul; 17(14):4901-14. PubMed ID: 21632860 [TBL] [Abstract][Full Text] [Related]
12. High sensitivity of reverse-hybridization methodology in the detection of KRAS mutations from formalin-fixed paraffin-embedded colorectal cancer samples. De Miglio MR; Mura A; Uras MG; Manca A; Contini M; Murgia L; Zinellu A; Sotgia S; Carru C; Massarelli G; Cossu-Rocca P Diagn Mol Pathol; 2010 Dec; 19(4):201-8. PubMed ID: 21052001 [TBL] [Abstract][Full Text] [Related]
13. Detection of KRAS codon 12 and 13 mutations by mutant-enriched PCR assay. Chang YS; Er TK; Lu HC; Yeh KT; Chang JG Clin Chim Acta; 2014 Sep; 436():169-75. PubMed ID: 24863805 [TBL] [Abstract][Full Text] [Related]
14. [The role of KRAS gene mutation testing in colorectal cancer--a predictive biomarker of response to EGFR inhibitors therapy]. Rako I; Jakić-Razumović J; Caban D; Sertić J; Katalinić D; Golem H; Plestina S Lijec Vjesn; 2011; 133(11-12):403-7. PubMed ID: 22329297 [TBL] [Abstract][Full Text] [Related]
15. Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma. Lee S; Brophy VH; Cao J; Velez M; Hoeppner C; Soviero S; Lawrence HJ Virchows Arch; 2012 Feb; 460(2):141-9. PubMed ID: 22173329 [TBL] [Abstract][Full Text] [Related]
16. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090 [TBL] [Abstract][Full Text] [Related]
17. High-throughput screening of extended RAS mutations based on high-resolution melting analysis for prediction of anti-EGFR treatment efficacy in colorectal carcinoma. Ishige T; Itoga S; Sato K; Kitamura K; Nishimura M; Sawai S; Matsushita K; Suzuki K; Ota S; Miyauchi H; Matsubara H; Nakatani Y; Nomura F Clin Biochem; 2014 Dec; 47(18):340-3. PubMed ID: 25262986 [TBL] [Abstract][Full Text] [Related]
18. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. Van Cutsem E; Lenz HJ; Köhne CH; Heinemann V; Tejpar S; Melezínek I; Beier F; Stroh C; Rougier P; van Krieken JH; Ciardiello F J Clin Oncol; 2015 Mar; 33(7):692-700. PubMed ID: 25605843 [TBL] [Abstract][Full Text] [Related]
19. KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma. Pang NK; Nga ME; Chin SY; Ismail TM; Lim GL; Soong R; Salto-Tellez M Cytopathology; 2011 Dec; 22(6):358-64. PubMed ID: 21029218 [TBL] [Abstract][Full Text] [Related]
20. KRAS mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectal cancer. Baynes RD; Gansert J Am J Ther; 2009; 16(6):554-61. PubMed ID: 19352138 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]